Analysis of the efficacy of recombinant interferon α1b in treatment of chronic hepatitis C
ZHANG Jing liang, GU Jing jing, TIAN Gui zhen
(Hospital of In fectious Diseases of Zibo City, Zibo 255067, China)
Abstract Objective: To study the efficacy and side effects of recombinant interferon α1b (Sinogen) in treatment of chronic hepatitis C. Methods: 65 patients were randomly divided to receive 30 μg.d-1 im Sinogen at weeks 1~4 and 30μg every 2 days im Sinogen at weeks 5~16(n=35), or receive placebo including drugs to reduce liver enzyme and jaundice and agent for liver protection(n=30). Results: ALT and SBIL were significantly decreased in both of the two groups, but the efficacy of the active arm was better than that of the control arm. The HCV eradication rate of the active arm was 37.1%,which was significantly higher than the corresponding figure(3.3%) of the control arm. Conclusion: Interferon α1b is an effective agent for treat ment of chronic hepatitis C.
Key words recombinant interferon α1b; chronic hepatitis C; side effects.
(1) Davis GL.Treat ment of Chronis Hepatitis B(J). hepatology,1991,14(3)∶567-570.
(2) 中华医学会传染病与寄生虫学会,病毒性肝炎防止方案(试行)(J),中华传染病杂志,1995,13(4)∶241-247
(3) 姚光弼,傅希贤,徐道振等,重组复合干扰素治疗慢性丙型肝炎的临床研究(J).中华传染病杂志,2000,18(2)∶101-105
(4) Davis,Hoofnagle Jh. Interferon in viral hepatitis: role in pathogerr esis and trest ment(J).Hepatology,1996,19(6)∶1038-1041.
干扰素α1b联合利巴韦林治疗慢性丙型肝炎64例作者: green120 时间: 2005-7-11 20:18
谢谢共享。